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Abstract 
 
 Chalcones (1,3-diphenylpropen-1-ones), a biosynthetic product of the shikimate 
pathway, belonging to flavanoid  family are precursors of open chain flavonoids and 
isoflavonoids, which are abundant in edible plants. They have a wide variety of 
cytoprotective and modulatory functions, which may have therapeutic potential for 
multiple diseases, especially as antitumor drugs. Several natural and synthetic chalcones 
and their derivatives appear as promising anticancer activities. Their chemical structure 
evaluation will be critical to assess their therapeutic utility. Those for which the 
mechanism of action is well defined can serve as lead compounds for the design of new, 
more promising molecules. The present review highlights the recently natural synthesized 
chalcones and their derivatives possessing important pharmacological activities as 
anticancer and how the mechanism pathways of these compounds in inhibiting cancer 
cells. 
 
Key words: chalcones; cancer treatment. 
 
INTRODUCTION 
Cancer is a group of diseases characterized by uncontrolled growth and spread of 
abnormal cells. If the spread is not controlled, it can result in death. Cancer is caused by both 
external factors (tobacco, infectious organisms, chemicals, and radiation) and internal factors 
(inherited mutations, hormones, immune conditions, and mutations that occur from 
metabolism). These causal factors may act together or in sequence to initiate or promote the 
development of cancer. Cancer is treated with surgery, radiation, chemotherapy, hormone 
therapy, biological therapy, and targeted therapy (American Cancer Society, 2012).  
In the United States and many other parts of the world, cancer is a serious public health 
issue. Currently, 1 in 4 deaths in the United States is due to cancer. It is estimated that 1,529,560 
new cancer cases and 569,490 deaths from cancer are projected to occur in the United States in 
2010 (Jemal et al., 2010). According to the data base of health research (Riskesdes, Health 
Department of Republic of Indonesia), the prevalence of tumors in Indonesia was 4.3 per 1000 
population (Depkes RI, 2007). Besides this, it is also predicted that cancer will overtake heart 
disease as the world's top killer by 2010 and this trend would make more than a double the 
global cancer cases and deaths by 2030 . So it is the time to better understand the prognosis, 
diagnosis and treatment of cancer . 
Chalcones (α,β-unsaturated ketones) are promising candidates in the new era of 
medicines on account of their wide spectrum of antitumor, antibacterial and anti-inflammatory 
activities (Sasayama et al., 2007; Ye et al. 2004; Ye et al., 2005; Lee et al., 2006; Haraguchi et 
al., 1998; Hsieh et al., 1998; Flechtner et al., 1979;  Chang et al., 2007; Rauf et al., 2005; and 
Pandey et al., 2007). However, the mechanisms of actions of this class of compounds are not yet 
fully understood, especially in anticancer. The purpose of this review is to provide an overview 
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of the anticancer activity of naturally occurring and synthetic chalcones. This review highlights 
more recent pharmacological screening of these compounds, their mechanisms of action and 
relevant structure-activity relationships. 
  
DISCUSSION 
1. Structure and Synthesis of Chalcones 
Chalcones, one of the major classes of natural products with widespread distribution in 
spices, tea, beer, fruits and vegetables, have been recently subject of great interest for their 
pharmacological activities (Dicarlo et al., 1999). Chalcones are precursor compounds for 
flavonoid synthesis in plants. Naturally occurring chalcones are found mostly in their 
hydroxylated forms, and have been reported to possess antiinflammatory, antimicrobial, 
antioxidant and anticancer properties  (Echeverria et al., 2009; Nowakowska et al., 2007; 
Miranda et al., 1999; Shah et al.,2008; Boumendjel et al., 2009; Katsori et al., 2009; Dimmock 
et al, 1999 and Go et al., 2005).  
Chalcones have crystal structure. They are α,β-unsaturated ketones consisting of two 
aromatic rings (ring A and B) having diverse array of substituents (figure 1). Rings are 
interconnected by a highly electrophilic three carbon α,β-unsaturated carbonyl system that 
assumes linear or nearly planar structure. They contain the ketoethylenic group (–CO–CH=CH). 
Chalcones possess conjugated double bonds and a completely delocalized π-electron system on 
both benzene rings (Rahman, 2011).  
 
 
 
 
 
 
 
 
 
Figure 1. (a) Structure of chalcone, (b) The energy minimazed 3D structure of chalcone 
 
Chalcones can be readily synthesized in laboratory by the Claisen-Schmidt reaction 
which is very easy and simple to conduct as well as inexpensive. The simplest chalcone can be 
prepared by an aldol condensation between a benzaldehyde and an acetophenone in the presence 
of sodium hydroxide as a catalyst (Arty, 2010). 
 
2. The Potential of Chalcones in Cancer Treatment 
a. Inhibition of activation NF- B by chalcone  
Cancer is regulated by a number of genes, which are in turn regulated by transcription 
factors. Among these transcription factors, NF-κB plays a major role in development and 
progression of cancer because it regulates more than 400 genes involved in inflammation, cell 
survival, cell proliferation, invasion, angiogenesis, apoptosis, cell cycle and metastasis. 
Incorrect regulation of NF- B may cause inflammatory and autoimmune diseases, viral 
infection and cancer (Yadav et al., 2011and Pahl, 1999).  
In tumor cells, NF-κB is active either due to mutations in genes encoding the NF-κB 
transcription factors themselves or in genes that control NF-κB activity (such as IκB genes); in 
addition, some tumor cells secrete factors that cause NF-κB to become active. Blocking NF-κB 
can cause tumor cells to stop proliferating, to die, or to become more sensitive to the action of 
anti-tumor agents. Thus, NF-κB is the subject of much active research among pharmaceutical 
companies as a target for anti-cancer therapy (Escárcega et al., 2007). 
 
(a) (b) 
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NF-κB  consists of homo- or heterodimers of the Rel family proteins, p50/NFκB1, p52/ 
NFκB2, p65/RelA, and c-Rel. In most cell types studied to date, in resting stage NF-κB dimers 
are retained in the cytoplasm through a physical association with inhibitor proteins, termed IκBα 
(Baeuerle et al., 1988). The classic form of NF- B is a heterodimer p50 and p65 subunits. 
Following cell activation, IκBα becomes hyperphosphorylated on distinct serine residues, and a 
mounting body of evidence indicates that this hyperphosphorylation targets the inhibitor for 
proteolytic degradation (Finco et al., 1995). The degradation of IκB eventually leads to its 
dissociation from NF-κB dimers, thereby allowing the movement of the latter towards the 
nucleus, where they may bind with high specificity to enhancer sequences in the 5′ regulatory 
region of target genes (figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The classical pathway of NF-kB activation (http://redox.fc.ul.pt/research.html.) 
 
NF-kB is often excessively activated in human solid tumor dan leukumias. Activation 
NF-kB in cancer cell may enhance cancer progression through the activation of cancer cell 
growth, apoptotic resistance, and increased metastatic activity. To treat or prevent diseases such 
as cancer that have an etiology based in inflammation, the agents that inhibit the inflammation 
and have no side effects be required. Among the candidates is chalcone, which is known as a 
potent anti-inflammatory agent.  
Chalcone and some derivate chalcones have been known to inhibit the activation of NF-
 B such as 2′,5′-dihydroxy-4-chloro-dihydrochalcone; Broussochalcone A; 3,4,5-trimethoxy-4′-
fluorochalcone; 3′,4′,5′,3,4,5-hexamethoxy-chalcone; Xanthoangelol D; 4-Hydroxyloncho-
carpin; Flavokawain A, B; 2′-hydroxychalcone; Cardamomin; Isoliquiritigenin;1,3-diphenyl-2-
propenone (chalcone); 2′-hydroxy-3-bromo-6′-methoxychalcone; 2′-methoxy-3,4-dichloro-
chalcone; Butein; Cardamonin; Hydroxysafflor yellow A; Licochalcone A; 2′,4′,6′-
tris(methoxymethoxy) chalcone; 3-hydroxy-4,3′,4′,5′-tetramethoxychalcone; Xanthohumol; and 
Isoliquiritigenin 2′-methyl ether (Yadav et al., 2011) through several mechanisms. Flavokavains 
A and B obtained from Piper methysticum cause inhibition of both IκB degradation and 
subsequent translocation of p50 and p65 NF-κB subunits from the cytoplasm to the nucleus 
(Folmer et al., 2006). Butein (3,4,2′,4′-tetrahydroxychalcone), natural compound obtained from 
stem-bark of cashews (Semecarpus anacardium), blocked the phosphorylation and degradation 
of IκBα by inhibiting IKK activation which is direct and involved cysteine residue 179. This 
correlated with the suppression of phosphorylation and the nuclear translocation of p65 (Pandey 
et al., 2007).  
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b. Chalcones arrests cell cycle progression and induces apoptosis 
Both normal cells and cancer cells have growth through a cell cycle. Regulation of cell 
cycle determines process of cell growth. In cancer cells occurs abnormal regulation of the cell 
cycle. Cell Cycle consists of proliferative phase, in the resting state (no cells divides, Go), and 
not permanently divide. Cells that are dividing divided into 4 (four) major phases: the gap phase 
1 (G1), synthesis phase (S), gap phase 2 (G2), and mitosis phase (M) (Foster et al., 2001 and 
Vermeulen et al., 2003). In normal cell, the cell cycle dependent on growth signals from the 
environment. If the signal is not sufficient growth, the cells are in the G1 phase of the cell cycle 
exit can enter the Go phase (Van den Heuvel, 2005). 
G1 phase is the phase when the cells prepare for DNA replication that will occur in the 
S phase, when DNA synthesis is complete the cell then enters the G2 phase, in this phase the 
cells prepare for cell division, when the cell is ready to enter the mitotic phase (M). Cells that 
are in the G1 phase may decide to enter into S phase or enter the Go phase. Go phase is the 
phase for on-proliferating cells (Lodish et al., 2000 and Vermeulen et al., 2003). The move from 
one phase to the next phase of the cell cycle is regulated by three main groups, namely cyclin 
proteins (cyclin D, cyclin E, cyclin A, and cyclin B), cyclin dependent kinases (CDKs, 
especially CDK4, CDK6, and CDK2), and cyclin dependent kinase inhibitors (CKIs) (King, 
2000).  
Disturbance in the cell cycle regulator will cause disruption of the program of cell 
cycle. In cancer cells, the cell cycle cannot be regulated so that cells become divided 
continually. Therefore, the development of research on cancer, cell cycle regulators is the 
potential for targeted anticancer drugs. 
Cancer cells are also able to avoid apoptosis mechanism. Apoptosis is cell death 
program that occurs as a result of the induction of the cell itself. Apoptosis can occur due to 
intrinsic factors when cells undergo irreversible damage DNA. Triggers apoptosis caused by 
extrinsic factors involving the role of tumor necrosis factor receptor, called the death receptors, 
viz. TNF - 2 receptor CD95 ( Fas/APO-1 ), and TRAIL receptor ( Lodish et al ., 2000). Proteins 
that play a role in the regulation of apoptosis are p53, Bcl-2 family proteins, Apaf, Caspase 
inhibitors pro apoptosis protein (as well as receptors that respond to death signals). Cells 
undergoing apoptosis has several characteristics, among others, increased expression pro 
apoptosis proteins ( Bax , Bid and Bak ) and suppression antiapoptosis protein expression (Bcl - 
2 and Bcl - xL), increased levels of cytosolic cytochrome C, caspase activation, PARP1 
activation, DNA fragmentation, and cell membrane damage. Accumulation of these 
characteristics led to the emergence of a variety of apoptotic bodies that result from cell 
fragmentation ( Gerl and Vaux, 2005) . 
Chalcone have been found to act through the intrinsic as well as extrinsic apoptosis 
pathway to prevent tumor progression. Basic structure of chalcone (1,3-diphenyl1-2-propenone) 
has proven to have a chemopreventive effect in human breast cancer cell lines: MCF-7 and 
MDA-MB-231 (Hsu et al. 2006) and human bladder cancer cell lines: T24 and HT-1376 (Shen 
et al. 2007). The research showed that chalcone inhibits the proliferation of  T24 and HT-1376 
cells by inducing apoptosis and blocking cell cycle progression in the G2/M phase. Chalcone 
significantly increases the expression of p21 and p27 proteins, and decreases the levels of cyclin 
B1, cyclin A and Cdc2, thereby contributing to cell cycle arrest. In addition, chalcone increased 
the expression of Bax and Bak, but decreased the levels of Bcl-2 and Bcl-XL and subsequently 
triggered mitochondrial apoptotic pathway (release of cytochrome c and activation of caspase-9 
and caspase-3). The induction of mitochondrial pathway and inhibition of the nuclear factor 
kappa B survival system may play important roles in the antiproliferative activity of chalcone in 
T24 and HT-1376 cells.  
Many natural chalcones have been shown to induce apoptosis in different types of 
cancer cells through a wide variety of mechanisms. Among the most important of these are 
xanthoangelol, flavokawain B, xanthohumol, isoliquiritigenin, flavokawin A, isobavachalcone, 
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cardamonin, licochalcone A, and butin (Table 1). These triterpenoids have a common target, 
Bcl-2 protein, which can induce apoptosis in cancer cells. 
Table 1. Molecular targets of known synthetic and natural chalcones for anticancer and anti- 
inflammatory activities chalcones 
Chalcone Targets 
2′,4′-dihydroxy-6′-methoxy-
3′,5′-dimethylchalcone 
NF-κB, KDR tyrosine kinase, Bim, Bcl-2, caspase-3, 
erbB-2 receptor, PARP, TNF-α, IL-6, IL-1β, iNOS 
4-Hydroxylonchocarpin NF-κB, MMP-2, iNOS 
Broussochalcone A NF-κB, iNOS, PKC, NADPH oxidase 
Butein 
 
NF-κB IAP2, Bcl-2, Bcl-xL, cyclin D1, c-Myc, COX-2 
MMP-9, DR5, STAT3, ICAM-1, Bax, caspase-3, EGFR 
TIMP-1, E- selectin, iNOS, JNK, IL-8, MMP-7, Mcl-1, 
hTERT, ATM, Chk1/2, cdc25C, Cdc2, Sp-1, VEGF, 
CXCR4 
Cardamomin NF-κB, TNF-α, COX-2, Akt, DR4/5, Bcl-xL, CHOP 
Cardamonin NF-κB, COX-1/2, TNF-α, iNOS, mTOR, P70S6K, 4E-
BP1 
Flavokawain A  NF-κB, Bax, Bcl-xL, XIAP, survivin, p27, p27, CDK1/2, 
Myt1, Wee1, cyclin B1, cdc25C 
Flavokawain B 
 
NF-κB, DR5, Bim, Puma, survivin, GADD153, PARP, 
Bid, caspase-8, Bak, cytochrome C, Bcl-2, iNOS, COX-
2, TNF-α, caspase-3/9, Bax, XIAP 
Hydroxysafflor yellow A NF-κB, TNF-α, ICAM-1, IL-1β, IL-6, IL-10, VEGF, 
p53, Bcl-2/ Bax ratio, HIF-1α, VHL, ET-1, iNOS 
Isobavachalcone caspases -3/9, Bax, A 
Isoliquiritigenin 
 
LOX-5/12, caspase-3/8/9, p53, p21, Fas/APO-1 receptor, 
FasL, Bax, NOXA, NF-κB, Bcl-xL, cIAP-1/2, COX-2, 
iNOS, cytochrome C, PARP, quinone reductasse, 
GADD153 
ICAM-1, VCAM-1, Bcl-2, MMP-2, ATM, Chk2, 
topoisomerase II, HO-1, IL-1β, TNF-α, cyclin B1/D1/E, 
CDK4, p27, cdc25c, IRF3, IP-10, RANTES, Nrf2, 
mTOR, VEGF, TLR4, uPA, MMP-9, TIMP-1 
Kanzonol C  MMP-2 
Licochalcone A 
 
NF-κB, COX-1/2, Bax, Bcl-2, STAT3, CD31, Ki-67, 
VEGFR2, iNOS, CCL2/MCP-1, CXCL1/KC, mTOR, 
TNFα, topoisomerase-1, cyclin B1/D1/E, Rb, cdc2, 
CDK4/6 
Naringenin chalcone IL-2, IL-4, IL-5, IL-13, INF-γ, TNF-α, MCP-1, p38 
MAPK 
Xanthoangelol NF-κB, caspases -3/9, VEGF, thromboxane B2, ET-1 
Xanthohumol 
 
NF-κB, Bax, p53, Akt, survivin, Bcl-xL, XIAP, cIAP1/2 
cyclin D1, c-myc, VEGF, PARP, caspase-3/7/8/9, Bcl-2 
Keap1, E- cadherin, TLR4, MD2, STAT1α, IRF-1, IL-1β 
p21, p53, Bcr- Abl, IL-2, IFN-γ, MCP-1, GRP78, Hsp70, 
PERK, ATF6, CHOP, Mcl-1, XBP-1, IL-8, IL-12 
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Chalcones influence invansion, metastasis and angiogenesis 
Tumor progression is a complex and multifaceted process that involves initiation, 
growth, invasion, and metastasis. Tumors would not grow beyond the limits of diffusion 
without stimulating a vascular system for the delivery of nutrients. Key stimulators and 
inhibitors of angiogenesis along with the tumor microenvironment regulate tumor growth. The 
relative concentrations of these stimulators and inhibitors determine endothelial cell phenotype, 
with the change from a quiescent to angiogenic phenotype referred to as the “angiogenic 
switch.” The tumor vasculature also provides tumor cells with a pathway through which to enter 
the circulation and metastasize.  
In metastasis the cancer cells migrate from their origin to other parts of the body, via 
either the bloodstream or lymphatic system. Migration and invasion of tumor cells are promoted 
by the loss of interaction of adherens junctions with the cytoskeleton, subsequent changes in the 
activities of Rho family small GTPases (most prominently Rac1, Cdc42, and RhoA), and the 
concomitant reorganization of the actin cytoskeleton (Noren et al., 2000 and Sahai et al., 2002). 
Among the factors influencing invasion, which affects whether or not a tumor will metastasize, 
are matrix metalloproteinase (MMPs) and ICAM-1. MMPs (specifically MMP2 and MMP9) are 
endopeptidases that degrade the basement membrane components separating the cells from their 
surrounding tissue and enabling them to move freely and spread to other tissues (Noujaim et al., 
2002).  
Vascular endothelial growth factor (VEGF) plays a unique role in physiological and 
pathological angiogenesis. VEGF promotes endothelial cell proliferation and migration, 
increases vascular permeability and inhibits apoptosis of endothelial cells lining newly formed 
vessels. There are numerous splice isoforms of VEGF that bind with varying degrees of affinity 
to VEGF receptors (VEGFR) on the surface of endothelial cells. Most of the angiogenic effects 
attributed to VEGF are a result of activation of VEGFR-2, which signals through the 
phosphatidyl-inositol 3 kinase (PI3K)/Akt pathway (Zachary, 2003).  
A few chalcones derived from natural sources have been shown to inhibit tumor cell 
invasion and metastasis by targeting one or more molecules (Table 1). Butein induces down-
regulation of MMP-9 gene in human leukemia cells in vitro (Pandey et al., 2007). The different 
compounds, kanzonol C, 4-hydroxylonchocarpin, paratocarpin, stipulin and dorsamanin A, are 
potential, naturally-occurring antitumor drugs that inhibit MMP-2 secretion from brain tumor-
derived glioblastoma cells (Ngameni et al., 2006).  
Chalcones also have potential to inhibit tumor angiogeneis, an important consideration 
because the growth of human tumors and development of metastases depends on the de novo 
formation of blood vessels (McMahon, 2000). These vessels enhance tumor growth by 
providing oxygen and nutrition. They also help tumor cells to migrate, invade, and metastasisze. 
Inhibition of the VEGF tyrosine kinase signaling pathway blocks new blood vessel formation in 
growing tumors, leading to stasis or regression of tumor growth. Xanthoangelo inhibits tumor-
induced neovascularization, inhibiting the formation of capillary-like tubes by vascular 
endothelial cells and inhibiting the binding of VEGF to vascular endothelial cells.  
Recently, the molecular docking study of chalcone derivate i.e. 3 - (4'-hydroxy-3'-
methoxyphenyl)-1-phenyl-2-propene-1-on showed that the binding energy of this compound 
with VEFGR (2P2I) almost had the same energy binding compared with ATP binding on 
VEFGR. Docking results between these compounds with the target protein VEGFR tyrosine 
kinase receptor showed the similarity of amino acids involved in their interaction (figure 3). It is 
expected this compound has potential as a cancer chemopreventive agent especially as anti 
angiogenesis (Arianingrum et al., 2013). 
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Figure 4 .  Interaction of 3 - (4'-hydroxy-3'-methoxyphenyl)-1-phenyl-2-propene-1-on (A) and 
ATP (B) with VEGFR (2P2I), showed the similarity of amino acid involved in their 
interaction (marked with boxes).  
Structure Activity Relationship of Chalcones 
Chalcone compounds have ortho- (i.e. 2′, 3′- and 3′,4′-) and para- (i.e. 2,5′-) 
substitutions. Chalcones possess conjugated double bonds and a completely delocalized Π-
electron system on both benzene rings. Molecules possessing such a system have relatively low 
redox potentials and have a greater probability of undergoing electron transfer reactions. The 
basic structure of chalcone (1,3-diphenyl-2-propenone) has NF- κB inhibitory activity at the 
concentration of 50 μM (Shen et al., 2007).  
Chalcones with substituents that increase the electronic density of the B-ring, such as 
methoxy, butoxy or dimethylamine groups, did not show significant activity in the inhibition of 
the nitrite production. The B- ring has a flexible ring structure and can easily convert cis-
chalcone to trans-chalcone or vice versa. Because of this reason, some of the chalcones that 
have a single substitution at the B-ring, like xanthohumol, isoliquiritigenin, butein, cardamonin, 
2′,5′-dihydroxy-4- chloro-dihydrochalcone, work best at higher concentrations (Israf et al., 
2007); Pandey et al., 2007; Harikumar et al., 2009; Huang et al., 2001; Kumar et al., 2007). At 
the same time some natural and synthetic chalcones with trimethoxy in the B-Ring act by 
inhibiting nitrite production. If there is trimethoxy chalcone at the A-ring with fluoro, chloro, 
bromo substitution in on the B-Ring, like 2′-hydroxy-3-bromo-6′-methoxychalcone, 2′- 
methoxy-3,4-dichlorochalcone, Flavokawain A, or Flavokawain B, then they are better 
inhibitors of NF-κB (Folmer et al., 2006 and Kim et al., 2007).  
Srinivasan et al (2009) synthesized chalcones with trimethoxy substitutions in the A-
ring and hydroxyl substitutions in the B-ring. They found that the synthetic compound 1, 2, 3, 
and 4 inhibited NF-κB even at lower concentrations between 1-8 μM. All the chalcones showed 
NF-κB inhibition containeda highly electrophilic α,β-unsaturated carbonyl moiety. This α,β-
unsaturated carbonyl moiety can act as an electrophile and react with free sulfhydryl groups of 
thioredoxin and cysteine residues in proteins . Foresti et al (2005) and Srinvisan et al (2009) 
indicated that electrophilic phytochemicals could give rise to thiyl radicals leading to alkene 
reduction through a covalent Michaelis addition of nucleophiles, such as SH from cystin from 
DNA, which binds to NF-κB.  
 
Docking score energy: -86.9007 Docking score energy: -86.9007 
A B 
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CONCLUSION AND SUGGESTION 
From the above review, it can be said that chalcones and their derivatives display a wide 
range of anticancer activities in particular to their role in suppression of NF-κB-mediated 
inflammation and cancer. Chalcones are easy to synthesize, further enrich the structural 
diversity of the template through the introduction of features normally associated with ligand-
receptor interaction, namely hydrophobic groups, hydrogen bond donor and acceptor features. 
Chalcones are highly multifunctional and thus are promising as agents in the treatment of cancer 
because of their ability to block the NF-κB activation, induce apoptosis, and to inhibit 
proliferation, invasion, metastasis and angiogenesis. So these natural and synthesic chalcones 
may serve as lead compound for cancer drug development. 
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